POTENTIAL CARDIOTOXICITY WITH MITOXANTRONE

  • 1 January 1982
    • journal article
    • research article
    • Vol. 66  (8) , 1641-1643
Abstract
Mitoxantrone is a promising new agent developed to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity. In a phase II clinical trial for refractory metastatic breast cancer, congestive heart failure was observed in 4 of 31 high-risk patients during or after treatment with this drug. This report calls attention to that observation; recommendation is made that further evaluation of this agent include careful cardiac monitoring.